Cibc World Market Inc. Invests $680,000 in Revvity Inc. $RVTY

Cibc World Market Inc. bought a new position in Revvity Inc. (NYSE:RVTY) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,113 shares of the company’s stock, valued at approximately $680,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Sanctuary Advisors LLC purchased a new stake in Revvity during the second quarter valued at about $315,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Revvity in the 2nd quarter worth about $9,696,000. Clear Harbor Asset Management LLC purchased a new position in shares of Revvity in the 2nd quarter worth about $278,000. Bank of Nova Scotia acquired a new position in shares of Revvity in the 2nd quarter valued at about $2,308,000. Finally, Commerce Bank acquired a new position in shares of Revvity in the 2nd quarter valued at about $1,033,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Performance

NYSE:RVTY opened at $129.30 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.80 and a quick ratio of 1.50. Revvity Inc. has a 1-year low of $81.22 and a 1-year high of $129.80. The firm has a 50-day moving average of $113.52 and a two-hundred day moving average of $101.02. The stock has a market cap of $14.43 billion, a P/E ratio of 61.57, a PEG ratio of 2.30 and a beta of 1.07.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm had revenue of $729.69 million during the quarter, compared to the consensus estimate of $702.96 million. During the same quarter in the prior year, the business posted $1.18 earnings per share. Revvity’s revenue for the quarter was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, research analysts expect that Revvity Inc. will post 5.36 earnings per share for the current fiscal year.

Revvity Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 13th. Shareholders of record on Friday, October 23rd will be given a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date of this dividend is Friday, October 23rd. Revvity’s dividend payout ratio is presently 13.33%.

Revvity News Roundup

Here are the key news stories impacting Revvity this week:

• Positive Sentiment: Zacks Research raised its FY2026 EPS forecast to $5.38 from $5.25, slightly above the $5.36 consensus estimate. The firm also increased its FY2027 forecast to $5.86 from $5.77, while lifting Q1 2027 EPS to $1.17 and Q4 2027 EPS to $1.77. These revisions suggest improving expectations for longer-term earnings growth. Revvity analyst estimates
• Neutral Sentiment: Zacks maintained a Hold rating, limiting the bullish impact of the higher estimates. Revvity’s latest reported quarter also exceeded expectations, with EPS of $1.41 versus the $1.21 consensus and revenue of $729.7 million versus $703.0 million, although revenue declined 1.3% year over year.
• Neutral Sentiment: An analysis highlighted that Revvity faces a new test after its strong advance. With the shares near their annual high, investors may focus on whether future operating improvement can justify the recent valuation and momentum. Revvity faces a new test after its strong run
• Negative Sentiment: Zacks lowered several quarterly forecasts, including Q3 2026 EPS to $1.27 from $1.30, Q4 2026 EPS to $1.64 from $1.67, Q3 2027 EPS to $1.42 from $1.44, and Q2 2028 EPS to $1.62 from $1.64. The cuts indicate some uncertainty around near-term earnings momentum.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. TD Cowen reissued a “buy” rating on shares of Revvity in a research report on Wednesday, July 15th. Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. Stifel Nicolaus reduced their price target on shares of Revvity from $110.00 to $100.00 and set a “hold” rating on the stock in a research report on Wednesday, May 6th. Sanford C. Bernstein began coverage on shares of Revvity in a research note on Friday, June 26th. They set a “market perform” rating and a $115.00 price objective for the company. Finally, Weiss Ratings raised shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, July 30th. Three analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the stock. According to data from MarketBeat.com, Revvity has a consensus rating of “Hold” and a consensus price target of $108.36.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.